and a $4.2 billion deal with Seattle Genetics covering ADCs for breast cancer and other solid tumours. The deal-making activity signals Merck’s determination to stay at the forefront of cancer ...

a rare genetic disorder, later in February. A transaction for SpringWorks would rank as one of the biggest pharma deals for Merck in recent years and boost its efforts to build out its cancer ...

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

a drug candidate for the treatment of rare genetic disorder neurofibromatosis type 1, or NF1. Shares in SpringWorks jumped Monday after Reuters reported that the company was in talks with Merck ...

Merck KGaA sees forex-adjusted earnings growth ... has approved SpringWorks Therapeutics' drug to treat a type of rare genetic disorder, which causes tumors to grow in the tissue that covers ...

Merck (NYSE:MRK) announced Tuesday that the ... endorsed the approvals in December by issuing positive opinions. VHL disease, a rare genetic disorder characterized by blood vessel tumors ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Merck KGaA reaffirmed its strong performance ... in February 2025 for treating neurofibromatosis type 1 (NF1), a rare genetic disorder. According to GlobalData’s Pharma Intelligence Center ...